NZ235807A - Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease - Google Patents

Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease

Info

Publication number
NZ235807A
NZ235807A NZ235807A NZ23580790A NZ235807A NZ 235807 A NZ235807 A NZ 235807A NZ 235807 A NZ235807 A NZ 235807A NZ 23580790 A NZ23580790 A NZ 23580790A NZ 235807 A NZ235807 A NZ 235807A
Authority
NZ
New Zealand
Prior art keywords
glucocorticosteroid
controlled release
bowel disease
outer coating
capsules containing
Prior art date
Application number
NZ235807A
Other languages
English (en)
Inventor
Jan Ulmius
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ235807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Draco Ab filed Critical Draco Ab
Publication of NZ235807A publication Critical patent/NZ235807A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ235807A 1989-11-22 1990-10-24 Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease NZ235807A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903914A SE8903914D0 (sv) 1989-11-22 1989-11-22 Oral composition for the treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
NZ235807A true NZ235807A (en) 1993-02-25

Family

ID=20377544

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ235807A NZ235807A (en) 1989-11-22 1990-10-24 Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease

Country Status (36)

Country Link
US (1) US6423340B1 (forum.php)
EP (1) EP0502092B1 (forum.php)
JP (1) JP3145111B2 (forum.php)
KR (1) KR0179042B1 (forum.php)
AT (1) ATE125445T1 (forum.php)
AU (1) AU643021B2 (forum.php)
CA (1) CA2071518C (forum.php)
DE (1) DE69021214T2 (forum.php)
DK (1) DK0502092T3 (forum.php)
EG (1) EG19642A (forum.php)
ES (1) ES2074698T3 (forum.php)
FI (2) FI104949B (forum.php)
GR (1) GR3017691T3 (forum.php)
HK (1) HK51897A (forum.php)
HR (1) HRP920632B1 (forum.php)
HU (2) HU216836B (forum.php)
IE (1) IE74854B1 (forum.php)
IL (1) IL96415A (forum.php)
IS (1) IS1858B (forum.php)
LT (1) LT3696B (forum.php)
LV (1) LV10183B (forum.php)
MY (1) MY104535A (forum.php)
NO (1) NO304010B1 (forum.php)
NZ (1) NZ235807A (forum.php)
PL (1) PL166506B1 (forum.php)
PT (1) PT95946A (forum.php)
RU (1) RU2134104C1 (forum.php)
SA (1) SA90110123B1 (forum.php)
SE (1) SE8903914D0 (forum.php)
SG (1) SG54210A1 (forum.php)
SI (1) SI9012150A (forum.php)
TW (1) TW250435B (forum.php)
UA (1) UA37196C2 (forum.php)
WO (1) WO1991007172A1 (forum.php)
YU (1) YU48583B (forum.php)
ZA (1) ZA908777B (forum.php)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
DK0678097T3 (da) * 1993-01-08 2000-02-07 Astra Ab Hidtil ukendte colon- eller ileumspecifikke steroidderivater
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4332394A1 (de) * 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
AU739031B2 (en) * 1996-11-15 2001-10-04 Procter & Gamble Company, The Pharmaceutical dosage form for colonic delivery
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
SE9902673D0 (sv) * 1999-07-12 1999-07-12 Astra Ab New composition
US8263582B2 (en) * 2001-03-15 2012-09-11 Soligenix, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
DE10250543A1 (de) * 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
US20060188563A1 (en) * 2003-03-27 2006-08-24 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
AU2004271743B2 (en) * 2003-09-15 2010-06-10 Covis Pharma B.V. Use of ciclesonide for the treatment of inflammatory bowel diseases
CA2538419C (en) 2003-09-16 2012-07-03 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
US8461187B2 (en) 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
WO2007056539A2 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
KR20090122489A (ko) * 2007-03-26 2009-11-30 데이코쿠 세이야쿠 가부시키가이샤 결장-특이적 전달을 위한 경구적 약제학적 제제
KR20150084013A (ko) * 2007-10-12 2015-07-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
JP5740306B2 (ja) * 2008-10-03 2015-06-24 ドクトル ファルク ファルマ ゲーエムベーハー メサラミン顆粒を用いて腸疾患を治療するための組成物および方法
US8945616B2 (en) 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
US8945615B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
CA2826662A1 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
MD480Z5 (ro) * 2011-07-07 2012-09-30 Эльвира АНДОН Metodă de tratament al colitei ulceroase nespecifice acute
ES2655622T3 (es) 2012-04-30 2018-02-20 Tillotts Pharma Ag Una formulación de fármaco de liberación retardada
BR112016004863B1 (pt) 2013-10-29 2022-09-20 Tillotts Pharma Ag Formulação de droga de liberação retardada
WO2017042835A1 (en) * 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical dosage forms of budesonide
CN105663091A (zh) * 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
RU2750937C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
RU2750944C2 (ru) * 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996356A (en) 1969-07-02 1976-12-07 Hoffmann-La Roche Inc. Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
SE378109B (forum.php) 1972-05-19 1975-08-18 Bofors Ab
SE7813246L (sv) 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
SE8003805L (sv) 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
SE8008524L (sv) 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
SE8306370D0 (sv) 1983-11-18 1983-11-18 Draco Ab Novel androstane-17beta-carboxylic acid esters, a process and intermediates for their preparation, compositions and method for the treatment of inflammatory conditions
US4708867A (en) 1983-12-19 1987-11-24 Key Pharmaceuticals, Inc. Minipellets
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
DE3536267A1 (de) 1985-10-11 1987-04-16 Bayer Ag Azofarbstoffe sowie fluessigkristallines material enthaltend azofarbstoffe
SE8506015D0 (sv) 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE10307386A1 (de) 2003-02-21 2004-09-09 Dieter Wildfang Gmbh Verfahren zum außenseitigen Beschichten eines sanitären Auslaufteiles sowie sanitäres Auslaufteil

Also Published As

Publication number Publication date
NO922004L (no) 1992-05-21
JP3145111B2 (ja) 2001-03-12
CA2071518A1 (en) 1991-05-23
LV10183A (lv) 1994-10-20
PT95946A (pt) 1991-09-13
AU643021B2 (en) 1993-11-04
ATE125445T1 (de) 1995-08-15
UA37196C2 (uk) 2001-05-15
AU7786491A (en) 1991-06-13
YU48583B (sh) 1998-12-23
FI104949B (fi) 2000-05-15
MY104535A (en) 1994-04-30
IS3644A7 (is) 1991-05-23
JPH05501705A (ja) 1993-04-02
IS1858B (is) 2003-03-27
EP0502092B1 (en) 1995-07-26
PL287844A1 (en) 1991-12-02
HU216836B (hu) 1999-09-28
EP0502092A1 (en) 1992-09-09
ES2074698T3 (es) 1995-09-16
SE8903914D0 (sv) 1989-11-22
YU215090A (sr) 1996-01-09
IL96415A0 (en) 1991-08-16
EG19642A (en) 1995-08-30
NO304010B1 (no) 1998-10-12
FI19991893A7 (fi) 1999-09-06
SI9012150A (sl) 1998-08-31
SA90110123B1 (ar) 1999-06-06
HRP920632B1 (en) 1999-10-31
DE69021214T2 (de) 1996-01-04
HUT60630A (en) 1992-10-28
LTIP1751A (en) 1995-07-25
HRP920632A2 (en) 1995-04-30
DK0502092T3 (da) 1995-12-27
FI922325A0 (fi) 1992-05-21
IL96415A (en) 1995-11-27
ZA908777B (en) 1991-07-31
HK51897A (en) 1997-05-02
HU9201700D0 (en) 1992-08-28
TW250435B (forum.php) 1995-07-01
LT3696B (en) 1996-02-26
KR920703025A (ko) 1992-12-17
KR0179042B1 (ko) 1999-03-20
IE74854B1 (en) 1997-08-13
NO922004D0 (no) 1992-05-21
PL166506B1 (pl) 1995-05-31
FI922325L (fi) 1992-05-21
LV10183B (en) 1995-08-20
FI19991893L (fi) 1999-09-06
DE69021214D1 (de) 1995-08-31
IE904170A1 (en) 1991-05-22
SG54210A1 (en) 1998-11-16
GR3017691T3 (en) 1996-01-31
RU2134104C1 (ru) 1999-08-10
CA2071518C (en) 2002-11-12
US6423340B1 (en) 2002-07-23
WO1991007172A1 (en) 1991-05-30

Similar Documents

Publication Publication Date Title
NZ235807A (en) Controlled release pellet formulation (core coated with or comprising a glucocorticosteroid, and a polymeric outer coating); capsules containing pellets; and use in treating bowel disease
IL118240A0 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
WO2001012122A3 (en) Method and system for treating cardiac arrest using hypothermia
CA2338780A1 (en) Preparation capable of releasing medicinal substance at targeted site in intestine
GEP20043334B (en) Hydrogel-Driven Drug Dosage Form
KR880003617A (ko) 경구용 고형제형과 그의 제조방법
CA2424029A1 (en) Coated medical devices
MX9604354A (es) Nueva forma de dosis farmaceutica oral.
EP1123087A4 (en) ORAL SYSTEM FOR THE ADMINISTRATION OF PULSED DOSES OF A MEDICAMENT
CA2104699A1 (en) Sustained release drug delivery devices
PH25905A (en) A controlled release pharmaceutical dosage form
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
NZ337216A (en) controlled-release microgranules containing cisplatin having a mean particle size of 0.4-1.5mm
EP0171528A3 (en) Controlled release pharmaceutical preparations
EP0425298A3 (en) Sustained-release preparation of basic medical agent hydrochloride
Kaplan et al. Quinolones for the treatment and prophylaxis of tuberculosis
Scher Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration
MY103627A (en) A controlled release pharmaceutical dosage form and a process for preparing same.
MX9710126A (es) Compuestos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que los contienen.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)